Pharmacotherapeutic options for overweight adolescents (Q36891391)

16 August 2017

1 reference

title

Pharmacotherapeutic options for overweight adolescents (English)

1 reference

16 August 2017

1 reference

Kaelen C Dunican

1

1 reference

16 August 2017

Alicia R Desilets

series ordinal

2

1 reference

16 August 2017

Julie K Montalbano

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

24 July 2007

1 reference

Annals of Pharmacotherapy

16 August 2017

1 reference

16 August 2017

41

1 reference

16 August 2017

9

1 reference

16 August 2017

1445-1455

1 reference

Epidemiologic trends in overweight and obesity

16 August 2017

1 reference

Prevalence of overweight and obesity in the United States, 1999-2004

21 January 2018

1 reference

Predicting obesity in young adulthood from childhood and parental obesity.

21 January 2018

1 reference

Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents

21 January 2018

1 reference

The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study.

21 January 2018

1 reference

Risks and consequences of childhood and adolescent obesity

21 January 2018

1 reference

Obesity and the metabolic syndrome in children and adolescents

21 January 2018

1 reference

Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

Current and investigational antiobesity agents and obesity therapeutic treatment targets

21 January 2018

1 reference

Intensive therapies for pediatric obesity

21 January 2018

1 reference

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

21 January 2018

1 reference

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial.

21 January 2018

1 reference

Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

21 January 2018

1 reference

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

21 January 2018

1 reference

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

Zonisamide for weight loss in obese adults: a randomized controlled trial

21 January 2018

1 reference

The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes

21 January 2018

1 reference

Beneficial effects of metformin in normoglycemic morbidly obese adolescents

21 January 2018

1 reference

Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin.

21 January 2018

1 reference

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

21 January 2018

1 reference

Pharmacotherapy for obesity.

21 January 2018

1 reference

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions

21 January 2018

1 reference

Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions

21 January 2018

1 reference

Addition of orlistat to conventional treatment in adolescents with severe obesity

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents

21 January 2018

1 reference

Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial

21 January 2018

1 reference

The Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents

21 January 2018

1 reference

Effects of orlistat on fat-soluble vitamins in obese adolescents

21 January 2018

1 reference

Randomized trial of lifestyle modification and pharmacotherapy for obesity

21 January 2018

1 reference

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial

21 January 2018

1 reference

Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study

21 January 2018

1 reference

Use of sibutramine in obese Hispanic adolescents

21 January 2018

1 reference

Effects of sibutramine treatment in obese adolescents: a randomized trial.

21 January 2018

1 reference

Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.

21 January 2018

1 reference

Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services.

21 January 2018

1 reference

Prevalence and trends in overweight among US children and adolescents, 1999-2000

21 January 2018

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1001/JAMA.288.14.1728

Identifiers

DOI

10.1345/APH.1K022

1 reference

16 August 2017

1 reference